ADRO News Aduro Biotech Inc 33.09 $ADRO Almaden
Post# of 11
Posted On: 12/16/2015 2:32:13 PM
ADRO News Aduro Biotech Inc 33.09 $ADRO
Almaden Announces Ixtaca Gold-Silver Deposit PEA Update Showing Significant Capital Savings Using the Rock Creek Mill
Marketwired - Wed Dec 09, 3:14PM CST
Almaden Minerals Ltd. ("Almaden" or "the Company"
(TSX: AMM) (NYSE MKT: AAU) is pleased to report positive results from an updated National Instrument (NI) 43-101 compliant Preliminary Economic Assessment ("PEA Update" on its 100% owned Ixtaca Gold-Silver deposit, Mexico which incorporates the benefits of the Company's recently announced option to purchase the Rock Creek Mill.
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Minerals Ltd. Announces Closing of $3,380,000 Non-Brokered Private Placement
Marketwired - Tue Nov 17, 3:17PM CST
Almaden Minerals Ltd. ("Almaden" or the "Company" (TSX: AMM)(NYSE MKT: AAU) is pleased to announce that it has closed a non-brokered private placement involving the issuance of 4,506,666 units ("Units" at $0.75 per Unit. Each Unit consists of one common share of the Company and one-half of one non-transferable common share purchase warrant (each such whole share purchase warrant, a "Warrant" . Each Warrant allows the holder to purchase one common share of the Company at a price of $1.00 per share until November 17, 2017. Fees consisting of $44,000 in cash and warrants to purchase up to 35,200 common shares at a price of $0.77 per common share until November 17, 2017 were paid to finders on a portion of the placement.
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Files Amended 2014 Technical Report
Marketwired - Mon Nov 09, 4:18PM CST
Almaden Minerals Ltd. ("Almaden" or the "Company" (TSX: AMM) (NYSE MKT: AAU) announces that as a result of a review by the British Columbia Securities Commission, we are issuing the following news release to clarify our disclosure. The review identified filing and disclosure issues with the technical report titled, NI 43-101 Technical Report Preliminary Economic Assessment of the Ixtaca Project, Mexico ("the Report" filed on October 9th, 2014. The Company has amended the report accordingly, which has now been refiled on SEDAR as an amended report. The Company wishes to clarify that the amendments are not material changes and the Report's data, inputs, interpretation, conclusions and results all remain unchanged. The items amended according to NI 43-101 guidelines are listed below in order of appearance in the original report.
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
AndeanGold Announces Up-Date on Management
ACCESSWIRE - Mon Oct 19, 3:02PM CDT
VANCOUVER, BC / ACCESSWIRE / October 19, 2015 / AndeanGold Ltd. (TSXV: AAU) (BVL: AAU) ("the Company" or "AndeanGold" is pleased to announce that Mr. Alberto E. Paz, a current director of the Company, has been appointed as the interim Chief Financial Officer for the Company. He fills the position vacated by the former Chief Financial Officer, which was announced on August 4, 2015.
AAU: 0.57 (+0.02), AAU.VN: 0.020 (+0.010)
Almaden Enters Into Mill Purchase Option Agreement; Significantly Reduces Capital Cost of Ixtaca "Ramp-Up" Scenario
Marketwired - Mon Oct 19, 3:00PM CDT
Almaden Minerals Ltd. ("Almaden" or the "Company" (TSX: AMM)(NYSE MKT: AAU) is pleased to announce that it has entered into an option agreement entitling it to purchase assets (the "Assets" which, when taken together, constitute the Rock Creek mill. The Rock Creek mill is located just outside of Nome, Alaska. The mill was built to process 7,000 tonnes per day, and includes a three-stage crushing plant, gravity circuit, ball mill, flotation cells and leaching facilities. Also included in the Assets are conveyors, metallurgical and chemical fire assay laboratories, a water treatment plant, full electrical circuitry including generators, and a number of spare parts for the ball mill and crushers. The Rock Creek mill only operated for several months before the mining operation was curtailed in 2008 and has been kept in excellent condition during subsequent care and maintenance.
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Issues Inaugural CSR Report
Marketwired - Wed Sep 16, 3:00PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" ; (TSX: AMM); (NYSE MKT: AAU) is pleased to announce that it has issued its inaugural report concerning its community-related activities at the Ixtaca project in Puebla State, Mexico.
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
AndeanGold Announces Up-Date on Audited Financial Statements and Default Status
ACCESSWIRE - Tue Sep 15, 2:20PM CDT
VANCOUVER, BC / ACCESSWIRE / September 15, 2015 / AndeanGold Ltd. (TSXV: AAU) (BVL: AAU) ("the Company" or "AndeanGold" reports that, further to its news releases of August 4, 2015, August 13, 2015 and August 27, 2015 announcing the delay in the filing date of its audited financial statements and the subsequent granting of a Management Cease Trade Order by the British Columbia Securities Commission on July 30, 2015, the Company is continuing its search for a new Chief Financial Officer and is endeavoring to complete its audit as early as is practicable.
AAU: 0.57 (+0.02), AAU.VN: 0.020 (+0.010)
Almaden Provides Ixtaca Metallurgical Program Update: Confirms High Limestone Gravity/Flotation/Leach Recoveries for Gold and Silver
Marketwired - Mon Sep 14, 3:07PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM) (NYSE MKT: AAU) is pleased to report on the Company's 100% owned Ixtaca gold-silver deposit located in Puebla State, Mexico and the progress of its on-going Pre-Feasibility ("PFS" level metallurgical test work program. The focus of the ongoing metallurgical test work program has been on the limestone material. Reported today are preliminary, non-optimised results from the leaching flotation concentrates. Key results of the test work reported today include the following:
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Confirms Almadex Trading Date
Marketwired - Thu Aug 13, 3:35PM CDT
Almaden Minerals Ltd. ("Almaden" or the "Company" (TSX: AMM) (NYSE MKT: AAU) is pleased to announce that the TSX Venture Exchange (the "TSXV" has issued a bulletin stating that the common shares (the "Almadex Shares" of Almadex Minerals Limited ("Almadex" will commence trading on the TSXV at the open of trading on Friday, August 14, 2015. The Almadex Shares will trade under the symbol "AMZ".
AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02), AMZ.VN: 0.150 (unch)
Anchor BanCorp Wisconsin Inc. Reports Third Quarter Earnings of $15.5 Million or $1.62 Per Diluted Share
GlobeNewswire - Thu Oct 29, 8:30AM CDT
Anchor BanCorp Wisconsin Inc. (the "Company" (NASDAQ:ABCW), and its wholly-owned subsidiary, AnchorBank, fsb (the "Bank" , today announced financial results for the quarter ended September 30, 2015. The Company recorded a profitable quarter with net income of $15.5 million, or $1.62 per diluted common share. Pre-tax net income for the quarter ended September 30, 2015 of $25.9 million, or $2.71 per diluted share, included a negative provision for loan losses of $22.4 million, or $2.34 per diluted share, which was partially offset by $1.5 million in expense related to early lease termination expenses associated with several previously announced operational efficiency initiatives. Management anticipates these operational efficiency initiatives will result in annual net cost savings of approximately $5.4 million related to reduced compensation, occupancy and other operating costs.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Reports Second Quarter Earnings of $107.5 Million or $11.37 Diluted Earnings Per Share Including a $103.0 Million Reversal of the Deferred Tax Asset Valuation Allowance
GlobeNewswire - Thu Jul 30, 4:30PM CDT
Anchor BanCorp Wisconsin Inc. (the "Company" (NASDAQ:ABCW) and its wholly-owned subsidiary, AnchorBank, fsb (the "Bank" today announced its financial results for the quarter ended June 30, 2015. The Company recorded a strong and profitable quarter with net income of $107.5 million or $11.37 per diluted common share. Net income for the quarter ended June 30, 2015 includes a one-time income tax benefit, net of current quarter provision, of $103.0 million or $10.89 per diluted share primarily resulting from the reversal of substantially all of the Company's net deferred tax asset valuation allowance. Pre-tax income of $4.5 million or $0.48 per diluted share included the impact of one-time gains and costs associated with several previously announced operational efficiency initiatives during the quarter ended June 30, 2015. Management anticipates these initiatives will result in annual net cost savings of approximately $5.4 million related to reduced compensation, occupancy and other operating costs.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Second Quarter 2015 Earnings Release Date and Conference Call
GlobeNewswire - Thu Jul 30, 3:30PM CDT
Second Quarter Financial Results Scheduled for Release
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Results of Operational Efficiency Measures
GlobeNewswire - Tue Jun 30, 4:45PM CDT
Anchor BanCorp Wisconsin Inc. (the "Company" (NASDAQ:ABCW) today announced the anticipated financial results of the operational efficiency measures introduced previously. As the Company announced on April 9, 2015, AnchorBank, fsb ("AnchorBank" , a wholly owned subsidiary of the Company, has taken several actions to address and improve overall operational efficiency. Management anticipates that these actions will result in an annual net cost savings related to reduced compensation, occupancy and other operating costs of approximately $5.4 million. The actions will be completed by the third quarter of 2015.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Finalizes Sale of Viroqua Branch to Royal Bank
GlobeNewswire - Mon May 18, 8:30AM CDT
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has finalized the sale of its Viroqua retail banking branch to Royal Bank of Elroy, Wisconsin as previously announced. The transaction closed today following receipt of the necessary regulatory approvals and satisfaction of customary closing conditions. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin reports Q1 results
Seeking Alpha - at Seeking Alpha - Thu Apr 30, 8:11AM CDT
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Reports First Quarter Earnings of $6.1 Million or $0.65 Earnings Per Share
GlobeNewswire - Thu Apr 30, 8:00AM CDT
Anchor BanCorp Wisconsin Inc. (the "Company" (Nasdaq:ABCW) today announced its financial results for the quarter ended March 31, 2015. Anchor recorded a strong and profitable quarter with net income of $6.1 million or $0.65 per diluted common share.
ABCW: 44.47 (-0.24)
AnchorBank Takes Actions to Improve Operational Efficiency
GlobeNewswire - Thu Apr 09, 8:05AM CDT
Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW) today announced several actions to address and improve the Company's overall operational efficiency, following a successful recapitalization in late 2013 and initial public offering in 2014.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin EPS of $0.55
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 5:27AM CST
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Fourth Quarter and Year End Results
GlobeNewswire - Fri Feb 06, 5:30PM CST
Anchor BanCorp Wisconsin Inc. (the "Company" (Nasdaq:ABCW) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014. Anchor concluded a strong, profitable year with net income of $14.6 million or $1.60 per diluted common share.
ABCW: 44.47 (-0.24)
Quarterly Report Card: Special Research on Ames National, Anchor Bancorp,Anchor BanCorp Wisconsin, Arrow, and ASB Bancorp
PR Newswire - Thu Feb 05, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ames National (NASDAQ: ATLO), Anchor Bancorp (NASDAQ: ANCB), Anchor BanCorp Wisconsin (NASDAQ: ABCW), Arrow (NASDAQ: AROW), and ASB Bancorp (NASDAQ: ASBB). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AROW: 28.13 (+0.04), ATLO: 24.29 (+0.06), ASBB: 25.75 (-0.24), ABCW: 44.47 (-0.24), ANCB: 25.23 (-0.30)
Anchor BanCorp Wisconsin Inc. Announces Definitive Agreement to Sell Viroqua Branch
GlobeNewswire - Tue Jan 27, 5:35PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Viroqua branch to Royal Bank of Elroy, Wisconsin. The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of May 2015. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Finalizes Sale of Richland Center Branch to The Peoples Community Bank
GlobeNewswire - Wed Dec 31, 3:56PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has finalized the sale of its Richland Center branch to The Peoples Community Bank (Peoples) as previously announced. The transaction closed today following receipt of the necessary regulatory approvals and satisfaction of customary closing conditions. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. to Join Multiple Russell Indexes
GlobeNewswire - Fri Dec 19, 3:30PM CST
Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW) today announced that it was included on the preliminary list of quarterly initial public offering additions to the broad-market Russell Global(R), Russell 3000(R), Russell 2000(R) and Russell Microcap(R) Indexes to be effective at the close of the U.S. market on Friday, December 19, 2014, according to a preliminary list of additions posted December 15, 2014 on www.russell.com/indexes.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin reports Q3 profit
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:52PM CST
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Third Quarter Results
GlobeNewswire - Tue Nov 04, 4:07PM CST
Anchor BanCorp Wisconsin Inc. (the "Company" (Nasdaq:ABCW), today announced its financial results for the quarter ended September 30, 2014. Net income was $5.0 million for the quarter compared to $2.6 million in the quarter ended June 30, 2014 and compared to net income of $113.3 million for the quarter ended September 30, 2013. Earnings per share were $0.55 for the quarter compared to $0.29 for the quarter ended June 30, 2014, and $5.47 per share for the quarter ended September 30, 2013. Income per share available to common equity was $10.24 for the quarter ended September 30, 2013. The prior year quarter income includes non-recurring extinguishment of debt income of $134.5 million which occurred as part of the recapitalization transaction we completed in September, 2013.
ABCW: 44.47 (-0.24)
Anchor Bancorp Wisconsin Inc. Announces Definitive Agreement to Sell Richland Center Branch
GlobeNewswire - Thu Oct 30, 5:30PM CDT
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Richland Center retail banking branch to The Peoples Community Bank (Peoples). The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of December 2014. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
U.S. IPO Weekly Recap: With Just 3 IPOs, More Companies Postpone Than Go Public
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 26, 12:22PM CDT
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those...
ABCW: 44.47 (-0.24), PRTO: 13.38 (-0.60)
Nice start for Anchor BanCorp after IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:52AM CDT
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin prices IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 6:52AM CDT
ABCW: 44.47 (-0.24)
BUYINS.NET: DANG, NEWS, ARII, ACOR, IVZ, EJ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 16, 6:27AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of E Commerce China Dangdang Inc (NYSE
ANG), Newstar Financial Inc (NASDAQ:NEWS), American Railcar Industries Inc (NASDAQ:ARII), Acorda Therapeutics Inc (NASDAQ:ACOR), Invesco Ltd (NYSE:IVZ), E-House (China) Holdings Ltd (NYSE:EJ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NEWS: 8.35 (+0.30), ARII: 48.38 (-0.57), DANG: 7.19 (-0.01), IVZ: 31.60 (+0.26), ACOR: 39.30 (+0.83), EJ: 6.19 (+0.04)
Acorda Therapeutics Has Returned 19.4% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Mon Dec 14, 5:07PM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 19.41% as of today's recent price of $37.16.
ACOR: 39.30 (+0.83)
Acorda Presents Analyses on Use of Healthcare Services for Seizure Clusters at American Epilepsy Society Annual Meeting
Business Wire - Tue Dec 08, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced analyses from a study showing the effect of rescue medication for seizure clusters on both clinical outcomes and healthcare resource utilization. The study found there were more adverse outcomes and greater use of healthcare resources among those who did not always use a rescue medication to treat seizure clusters, compared to those who always used a rescue medication. Seizure clusters are defined as multiple, distinct seizures that occur over a 24-hour period. These analyses were presented at the 69th Annual Meeting of the American Epilepsy Society in Philadelphia, PA.
ACOR: 39.30 (+0.83)
Acorda Initiates Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines
Business Wire - Thu Dec 03, 6:01AM CST
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of migraines.
ACOR: 39.30 (+0.83)
BUYINS.NET: BFIN, SLW, CF, NEWS, ACOR, RZG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 02, 10:54PM CST
November 18, 2015
NEWS: 8.35 (+0.30), BFIN: 13.10 (+0.17), CF: 41.02 (+0.21), SLW: 12.56 (+0.01), ACOR: 39.30 (+0.83), RZG: 82.50 (+0.94)
NATIONAL DISABILITY INSTITUTE AND ACORDA THERAPEUTICS EXPAND FINANCIAL WELLNESS PROGRAM TO REACH MORE PEOPLE
GlobeNewswire - Wed Dec 02, 10:35AM CST
On December 9th, National Disability Institute (NDI) will launch the fifth annual Financial Wellness Program, designed to help people living with disabilities plan for their financial futures. Expert guests with backgrounds in law, finance and public benefits will share their insight on topics including taxes, employment, Social Security and credit. All resources and information presented will be specially tailored to address and remedy the unique financial challenges faced by individuals living with a range of disabilities. Last year, thousands of people registered for webinars, made available free of charge with support from Acorda Therapeutics.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Up 23.6% Since SmarTrend Uptrend Call (ACOR)
Comtex SmarTrend(R) - Mon Nov 30, 10:28AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 23.55% as of today's recent price of $38.45.
ACOR: 39.30 (+0.83)
Acorda Therapeutics to Present at the Oppenheimer Annual Healthcare Conference
Business Wire - Mon Nov 30, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Oppenheimer Healthcare Conference in New York on Tuesday, December 8 at 11:30 am.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Has Returned 20.6% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Mon Nov 23, 9:29AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 20.57% as of today's recent price of $37.52.
ACOR: 39.30 (+0.83)
Bristol-Myers' Opdivo Gets Priority Review from the FDA
Zacks Equity Research - Zacks Investment Research - Tue Nov 17, 12:50PM CST
Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.
GILD: 102.83 (+0.86), ABBV: 56.94 (+0.55), ACOR: 39.30 (+0.83), BMY: 69.74 (-0.48)
Shares of ACOR Up 19.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 16, 9:22AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 1 month, Acorda Therapeutics has returned 19.38% as of today's recent price of $37.15.
ACOR: 39.30 (+0.83)
Joel Marcus, CEO of Alexandria Real Estate Equities, Inc., Receives Lifetime Achievement Award from Biotech Executives
PR Newswire - Thu Nov 12, 7:54AM CST
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA urban innovation cluster locations, announced today that Joel S. Marcus, chairman, chief executive officer and founder, was honored with the NY/NJ CEO Lifetime Achievement Award in recognition of his leadership in the life science community. Mr. Marcus received the award on Wednesday, Nov. 11 during the NY/NJ CEO Conference, hosted by Boston Biotech Conferences, at the Apella(TM) event space at the Alexandria Center® for Life Science - New York City. The award was presented by esteemed past award honorees Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University; Ron Cohen, M.D., president and chief executive officer of Acorda Therapeutics, Inc. and George Yancopoulos, M.D., Ph.D., founding scientist, president and chief scientific officer of Regeneron Pharmaceuticals, Inc.
ARE: 90.03 (+0.38), ACOR: 39.30 (+0.83), REGN: 554.25 (-2.20)
Acorda Therapeutics to Present at Two Investor Conferences in November
Business Wire - Tue Nov 10, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during November.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Shares Up 20.7% Since SmarTrend's Buy Recommendation (ACOR)
Comtex SmarTrend(R) - Fri Nov 06, 4:47PM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 1 month, Acorda Therapeutics has returned 20.66% as of today's recent price of $37.55.
ACOR: 39.30 (+0.83)
Why Acorda Therapeutics (ACOR) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 7:52AM CST
Acorda Therapeutics is a biotechnology company that is seeing solid activity on the earnings estimate revision front
ACOR: 39.30 (+0.83)
Looking for a Top Momentum Stock? 3 Reasons Why Acorda Therapeutics (ACOR) is a Great Choice
Zacks Equity Research - Zacks Investment Research - Mon Nov 02, 7:47AM CST
Acorda Therapeutics has a great combination of momentum score and favorable Zacks Rank, which makes it an impressive pick
ACOR: 39.30 (+0.83)
Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 8:40AM CDT
Vertex's (VRTX) third quarter results were strong with the company posting a narrower-than-expected loss and revenues coming in well above expectations.
VRTX: 116.89 (-0.39), AMAG: 27.33 (+0.47), ACOR: 39.30 (+0.83)
Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents" .
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
BUYINS.NET: ACST SqueezeTrigger Price is $1.09. There is $12,810 That Short Sellers Still Need To Cover.
M2 - Thu Oct 15, 11:43AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ACCESS TRADEONE.COM (NASDAQ:ACST) in real time and just received an alert that ACST is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 4200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.09. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ACST: 2.37 (+0.76)
TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 2.37 (+0.76)
Acasti reports 2Q loss
Automated Insights - Wed Oct 14, 4:45PM CDT
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Wednesday reported a loss of $972,000 in its fiscal second quarter.
ACST: 2.37 (+0.76)
Acasti Announces Second Quarter Results
GlobeNewswire - Wed Oct 14, 4:10PM CDT
-- Important progress made in FDA discussions on development pathway for CaPre(R)
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti approves one for ten reverse stock split
M2 - Wed Sep 30, 5:23AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) declared on Tuesday that it will consolidate its issued and outstanding Class A common shares on the ratio of one post-consolidation common share for every ten pre-consolidation common shares provided each fractional common share shall be rounded up.
ACST: 2.37 (+0.76)
Acasti Announces 1-for-10 Reverse Stock Split
GlobeNewswire - Tue Sep 29, 6:00AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that in order to regain compliance with NASDAQ Minimum Bid Price Rules, it will consolidate the issued and outstanding Class A common shares ("Common Shares" of the Corporation (the "Consolidation" on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares (the "Consolidation Ratio" , provided that each fractional Common Share that results from the Consolidation shall be rounded up.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 305.98 (+1.32), ACST: 2.37 (+0.76), ISIS: 58.89 (+2.47), AZN: 33.49 (+0.23), TKMR: 10.83 (+0.58), CBAY: 1.44 (+0.04), NVS: 85.86 (+0.58)
Acasti announces award of incentive stock options to its board
M2 - Thu Aug 20, 3:10AM CDT
Acasti Pharma (Nasdaq CM:ACST) (TSX:APO.V) Wednesday awarded an aggregate of 500,000 incentive stock options.
ACST: 2.37 (+0.76)
Acasti Announces Grant of Stock Options
GlobeNewswire - Wed Aug 19, 4:05PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the grant of an aggregate of 500,000 incentive stock options under the Corporation's Stock Option Plan for its Board of Directors. The options will vest annually over a period of three years and will entitle its holder to purchase one common share of Acasti at a price of CDN $0.48 until August 19, 2022.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Mario Paradis Appointed CFO of Neptune and Acasti
GlobeNewswire - Wed Aug 05, 4:30PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (NASDAQ:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (NASDAQ:ACST) (TSX-V:APO), a Neptune subsidiary, announce the appointment of Mario Paradis as Chief Financial Officer (CFO), starting August 24, 2015.
ACST: 2.37 (+0.76), NTB.TO: 1.41 (+0.06), NEPT: 1.05 (+0.06), APO.VN: 3.320 (+1.100)
Acasti falls to Q1 net loss of USD966,000
M2 - Tue Jul 14, 4:39AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Monday its net loss of USD966,000 for the first quarter ended 31 May 2015.
ACST: 2.37 (+0.76)
Acasti Announces First Quarter Results
GlobeNewswire - Mon Jul 13, 4:05PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the first quarter ended May 31, 2015.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Pharma net loss improves in FQ4 and FY15
Seeking Alpha - at Seeking Alpha - Thu May 28, 7:23AM CDT
ACST: 2.37 (+0.76)
Acasti Pharma reports FQ4 results
Seeking Alpha - at Seeking Alpha - Wed May 27, 4:50PM CDT
ACST: 2.37 (+0.76)
Acasti Announces Fourth Quarter and Fiscal Year Results
GlobeNewswire - Wed May 27, 4:37PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its operating and financial results for the fourth quarter and fiscal year ended February 28, 2015.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of Shareholders
GlobeNewswire - Wed May 27, 4:35PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, today announced its slate of director nominees for election at its next Annual and Special Meeting ("ASM" of shareholders to be held on July 14, 2015. The slate is comprised of four current directors, and two new director nominees.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule
GlobeNewswire - Mon May 11, 9:48AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ" that it is eligible for an additional 180 calendar days, until November 2, 2015, to regain compliance with the minimum $1.00 per share requirement for continued listing.
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Zacks Investment Ideas feature highlights: Netgear, Activision Blizzard, AeroCentury, Biotelemetry and A-Mark Precious
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:30AM CST
Zacks Investment Ideas feature highlights: Netgear, Activision Blizzard, AeroCentury, Biotelemetry and A-Mark Precious
ATVI: 38.84 (+0.13), BEAT: 12.08 (+0.16), ACY: 12.25 (-0.70), NTGR: 43.99 (+0.50), AMRK: 17.26 (+0.63)
5 Strong Stocks in Stronger Industries
David Bartosiak - Zacks Investment Research - Thu Dec 03, 11:48AM CST
5 Strong Stocks in Stronger Industries
ATVI: 38.84 (+0.13), ACY: 12.25 (-0.70), BEAT: 12.08 (+0.16), NTGR: 43.99 (+0.50), AMRK: 17.26 (+0.63)
3 Reasons Value Stock Investors Will Love AeroCentury (ACY)
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 7:48AM CST
There are numerous reasons that make AeroCentury a great choice for value investors
ACY: 12.25 (-0.70)
Shares of ACY Down 14.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 17, 9:26AM CST
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 2 months, AeroCentury has returned 14.02% as of today's recent price of $8.65.
ACY: 12.25 (-0.70)
AeroCentury Corp. Earns $1.3 Million, or $0.81 per Share, in 3Q15; Portfolio Utilization Improves to 94%
PR Newswire - Mon Nov 09, 4:00PM CST
AeroCentury Corp. (NYSE MKT: ACY), an independent aircraft leasing company, today reported earnings totaling $1.3 million, or $0.81 per diluted share, in the third quarter of 2015, compared to $1.4 million, or $0.87 per diluted share, in the second quarter of 2015. Third quarter profits reflect an improvement in utilization as the Company continues to adjust the composition of its portfolio of regional aircraft and engines. Following the $11.7 million non-cash, pre-tax write-down of certain older aircraft, the net loss in the third quarter of 2014 was $8.2 million, or ($5.34) per diluted share.
ACY: 12.25 (-0.70)
AeroCentury Shares Down 12.1% Since SmarTrend's Sell Call (ACY)
Comtex SmarTrend(R) - Wed Nov 04, 12:19PM CST
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 12.09% as of today's recent price of $8.84.
ACY: 12.25 (-0.70)
8.7% Return Seen to Date on SmarTrend AeroCentury Call (ACY)
Comtex SmarTrend(R) - Wed Oct 28, 10:47AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 8.75% as of today's recent price of $9.18.
ACY: 12.25 (-0.70)
Why Rent-A-Center Stock Plunged after Q3 Earnings Results
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 9:50AM CDT
Although Rent-A-Center (RCII) continued with its positive earnings surprise streak for the third successive quarter, it missed on revenues and lowered its earnings forecast which took a toll on the stock.
RCII: 15.67 (+0.08), MGRC: 26.09 (+0.27), ACY: 12.25 (-0.70), AAN: 22.74 (+0.29)
AeroCentury Shares Down 9.5% Since SmarTrend's Sell Call (ACY)
Comtex SmarTrend(R) - Wed Oct 21, 9:37AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 9.54% as of today's recent price of $9.10.
ACY: 12.25 (-0.70)
AeroCentury Has Returned 13.1% Since SmarTrend Recommendation (ACY)
Comtex SmarTrend(R) - Tue Oct 13, 9:55AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 3 weeks, AeroCentury has returned 13.11% as of today's recent price of $8.74.
ACY: 12.25 (-0.70)
CBOE Holdings Well Poised on Business Model, Cost Control
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 2:55PM CDT
On Oct 6, 2015, we issued an updated research report on CBOE Holdings, Inc. (CBOE).
AER: 40.36 (+0.19), ACAS: 13.95 (-0.03), CBOE: 65.89 (-1.50), ACY: 12.25 (-0.70)
Downtrend Call Working As AeroCentury Stock Falls 13.5% (ACY)
Comtex SmarTrend(R) - Tue Oct 06, 9:42AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 2 weeks, AeroCentury has returned 13.52% as of today's recent price of $8.70.
ACY: 12.25 (-0.70)
Shares of ACY Up 21.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 15, 10:12AM CDT
SmarTrend identified an Uptrend for AeroCentury (AMEX:ACY) on August 24th, 2015 at $9.68. In approximately 3 weeks, AeroCentury has returned 21.38% as of today's recent price of $11.75.
ACY: 12.25 (-0.70)
CBOE Holdings to Launch AFX with Environmental Financial
Zacks Equity Research - Zacks Investment Research - Fri Sep 11, 9:20AM CDT
CBOE Holdings, Inc. (CBOE) recently entered into an agreement with Environmental Financial Products, LLC ("EFP" to form and launch American Financial Exchange ("AFX" .
CME: 95.00 (-0.15), ACAS: 13.95 (-0.03), CBOE: 65.89 (-1.50), ACY: 12.25 (-0.70)
AeroCentury Up 26.0% Since SmarTrend Uptrend Call (ACY)
Comtex SmarTrend(R) - Tue Sep 08, 9:47AM CDT
SmarTrend identified an Uptrend for AeroCentury (AMEX:ACY) on August 24th, 2015 at $9.68. In approximately 2 weeks, AeroCentury has returned 26.03% as of today's recent price of $12.20.
ACY: 12.25 (-0.70)
The Zacks Analyst Blog Highlights: AeroCentury, Central Garden & Pet, LGI Homes, NCI and U.S. Concrete
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: AeroCentury, Central Garden & Pet, LGI Homes, NCI and U.S. Concrete
LGIH: 25.87 (+1.02), CENT: 14.31 (-0.16), ACY: 12.25 (-0.70), NCIT: 14.60 (-0.37), USCR: 53.99 (+0.57)
5 Best Performing Stocks in August
Swarup Gupta - Zacks Investment Research - Tue Sep 01, 10:26AM CDT
Markets experienced a dismal month, weighed down by concerns about China and uncertainty over the timing of a rate hike.
LGIH: 25.87 (+1.02), CENT: 14.31 (-0.16), ACY: 12.25 (-0.70), DIS: 113.15 (+0.99), WMT: 60.16 (+0.52), NCIT: 14.60 (-0.37), VIAB: 41.14 (+0.16), USCR: 53.99 (+0.57)
New Strong Buy Stocks for August 21st
Zacks Equity Research - Zacks Investment Research - Fri Aug 21, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
PRSS: 3.74 (unch), FTD: 27.63 (+0.56), ACY: 12.25 (-0.70), EIG: 27.48 (-0.07), ANCB: 25.23 (-0.30)
Aduro's CRS-207/GVAX Pancreas Gets Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 3:20PM CST
Aduro's (ADRO) CRS-207/GVAX Pancreas combination gets Orphan drug designation in the EU.
ADRO: 33.08 (+1.94), ACHN: 9.82 (+0.11), ANIK: 38.17 (+0.67), CORT: 4.70 (+0.19)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 33.08 (+1.94), PFE: 32.26 (unch), ARQL: 2.16 (unch), BMY: 69.71 (-0.51), GSK: 39.85 (+0.51), VSTM: 1.82 (+0.08), SNTA: 0.32 (unch), MRK: 53.51 (+0.61), JUNO: 45.99 (-0.76), NVS: 85.83 (+0.55), CXRX: 38.15 (+0.54), FPRX: 42.31 (+2.07)
The Only Bit of "Good News" From 2015
ACCESSWIRE - Mon Dec 14, 10:08AM CST
WINDSOR, ON / ACCESSWIRE / December 14, 2015 / The Wealthy Biotech Trader (or "WBT" , an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to mention a few highlights from 2014/ 2015 in the crazy world of biotech investing.
IMMU: 3.04 (+0.12), ADRO: 33.08 (+1.94), MRK: 53.51 (+0.61), AMGN: 163.32 (+0.70), LLY: 85.00 (-0.52), THLD: 0.50 (+0.02), BMY: 69.71 (-0.51)
Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 and GVAX Pancreas for the Treatment of Pancreatic Cancer
GlobeNewswire - Mon Dec 14, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 and GVAX for the treatment of pancreatic cancer.
ADRO: 33.08 (+1.94)
Aduro Biotech doses first lung cancer patient under Phase 1 Study of ADU-214
M2 - Fri Dec 11, 3:44AM CST
Oncology company Aduro Biotech (NasdaqGS:ADRO) reported on Thursday that it has commenced treatment of the first patient in the Phase 1 study of ADU-214 for lung cancer.
ADRO: 33.08 (+1.94)
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer
GlobeNewswire - Thu Dec 10, 3:15PM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the start of the Phase 1 study of ADU-214 (also known as JNJ-64041757), a LADD immuno-oncology therapy for the treatment of lung cancer, with the dosing of the first patient in the trial. Janssen Biotech, Inc., Aduro's license partner for ADU-214, is conducting the multi-center study.
ADRO: 33.08 (+1.94)
Aduro Biotech to Present at Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 02, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer's 26 Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
ADRO: 33.08 (+1.94)
Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 28, 6:21AM CST
Source: Bristol-Myers Squibb. One of the most important new drugs to win regulatory approval this year is Opdivo, a novel medicine developed by Bristol-Myers Squibb that keeps cancer from evading detection by a patient's immune system. Opdivo...
ADRO: 33.08 (+1.94), BMY: 69.71 (-0.51), CELG: 113.93 (+0.79)
Aduro Biotech to Present at NASDAQ Investor Conference
GlobeNewswire - Fri Nov 27, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 33 NASDAQ Investor Conference in London, UK on Tuesday, December 1, 2015, at 8:00 am Greenwich Mean Time.
ADRO: 33.08 (+1.94)
Aduro Biotech Confirms All Clinical Trials Continue Unaltered and as Planned
GlobeNewswire - Tue Nov 24, 4:09PM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it will hold a conference call tomorrow November 25, 2015 at 5:00 am Pacific Standard Time. To participate in the conference call, please dial (855) 283-3941 (domestic) or (330) 863-3274 (international) and refer to conference ID 90656408. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the general public under the Investors section of the company's website at www.aduro.com.
ADRO: 33.08 (+1.94)
Why Aduro Biotech Is Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 24, 2:03PM CST
Source: Aduro BioTech W hat: After reporting that a patient developed a serious infection while receiving its promising immunotherapy for the treatment of pancreatic cancer, shares in Aduro BioTech fell by 15% earlier today. So...
ADRO: 33.08 (+1.94), BMY: 69.71 (-0.51)
Aduro Biotech tops Street 3Q forecasts
Automated Insights - Mon Nov 23, 7:09AM CST
BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Monday reported third-quarter profit of $567,000.
ADRO: 33.08 (+1.94)
Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma
GlobeNewswire - Mon Nov 23, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 for the treatment of malignant pleural mesothelioma (MPM).
ADRO: 33.08 (+1.94)
Aduro Biotech Announces Third Quarter 2015 Financial Results
GlobeNewswire - Mon Nov 23, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter and nine months ended September 30, 2015. Net income was $0.6 million for the third quarter of 2015, or $0.01 per share, and net loss was $42.3 million, or $1.09 per share, for the nine months ended September 30, 2015. This compares to a net loss of $4.7 million, or $14.24 per share, and $16.1 million, or $52.47 per share respectively, for the same periods in 2014.
ADRO: 33.08 (+1.94)
Aduro (ADRO) Creates Subsidiary, Aduro Biotech Europe
Zacks Equity Research - Zacks Investment Research - Fri Nov 20, 1:50PM CST
Aduro (ADRO) has established a subsidiary in the EU, which will operate as Aduro Biotech Europe.
ADRO: 33.08 (+1.94), ACHN: 9.82 (+0.11), ANIK: 38.17 (+0.67), CORT: 4.70 (+0.19)
Aduro Biotech Europe's Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured as Keynote Speaker on Immunomodulatory Antibodies at ESMO Symposium on Immuno-Oncology 2015
Thomson Reuters ONE - Fri Nov 20, 7:00AM CST
BERKELEY, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a clinical-stage immunotherapy company, today announced the presentation of an overview of novel antibody and combination strategies designed to stimulate durable anti-tumor response at the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology 2015, taking place November 20-21, 2015, in Lausanne, Switzerland. The presentation was featured in a keynote lecture delivered at the ESMO symposium by Andrea van Elsas, Ph.D., chief scientific officer of Aduro Biotech Europe, titled, "Immunomodulatory Antibodies Beyond PD-1."
ADRO: 33.08 (+1.94)
Aduro Biotech Establishes European Subsidiary
GlobeNewswire - Thu Nov 19, 3:05PM CST
-Recently Acquired BioNovion Site to Become Aduro Biotech Europe-
ADRO: 33.08 (+1.94)
Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-741 in Prostate Cancer
GlobeNewswire - Wed Nov 18, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it has received a milestone payment from Janssen Biotech, Inc. for Aduro's submission of an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer (mCRPC).
ADRO: 33.08 (+1.94)
Aduro Biotech Announces Five Poster Presentations at the Society of Immunotherapy of Cancer Annual Meeting
GlobeNewswire - Mon Nov 09, 7:00AM CST
Posters highlight:
ADRO: 33.08 (+1.94)
Almaden Announces Ixtaca Gold-Silver Deposit PEA Update Showing Significant Capital Savings Using the Rock Creek Mill
Marketwired - Wed Dec 09, 3:14PM CST
Almaden Minerals Ltd. ("Almaden" or "the Company"
(TSX: AMM) (NYSE MKT: AAU) is pleased to report positive results from an updated National Instrument (NI) 43-101 compliant Preliminary Economic Assessment ("PEA Update" on its 100% owned Ixtaca Gold-Silver deposit, Mexico which incorporates the benefits of the Company's recently announced option to purchase the Rock Creek Mill. AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Minerals Ltd. Announces Closing of $3,380,000 Non-Brokered Private Placement
Marketwired - Tue Nov 17, 3:17PM CST
Almaden Minerals Ltd. ("Almaden" or the "Company"
(TSX: AMM)(NYSE MKT: AAU) is pleased to announce that it has closed a non-brokered private placement involving the issuance of 4,506,666 units ("Units" at $0.75 per Unit. Each Unit consists of one common share of the Company and one-half of one non-transferable common share purchase warrant (each such whole share purchase warrant, a "Warrant" . Each Warrant allows the holder to purchase one common share of the Company at a price of $1.00 per share until November 17, 2017. Fees consisting of $44,000 in cash and warrants to purchase up to 35,200 common shares at a price of $0.77 per common share until November 17, 2017 were paid to finders on a portion of the placement. AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Files Amended 2014 Technical Report
Marketwired - Mon Nov 09, 4:18PM CST
Almaden Minerals Ltd. ("Almaden" or the "Company"
(TSX: AMM) (NYSE MKT: AAU) announces that as a result of a review by the British Columbia Securities Commission, we are issuing the following news release to clarify our disclosure. The review identified filing and disclosure issues with the technical report titled, NI 43-101 Technical Report Preliminary Economic Assessment of the Ixtaca Project, Mexico ("the Report" filed on October 9th, 2014. The Company has amended the report accordingly, which has now been refiled on SEDAR as an amended report. The Company wishes to clarify that the amendments are not material changes and the Report's data, inputs, interpretation, conclusions and results all remain unchanged. The items amended according to NI 43-101 guidelines are listed below in order of appearance in the original report. AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
AndeanGold Announces Up-Date on Management
ACCESSWIRE - Mon Oct 19, 3:02PM CDT
VANCOUVER, BC / ACCESSWIRE / October 19, 2015 / AndeanGold Ltd. (TSXV: AAU) (BVL: AAU) ("the Company" or "AndeanGold"
is pleased to announce that Mr. Alberto E. Paz, a current director of the Company, has been appointed as the interim Chief Financial Officer for the Company. He fills the position vacated by the former Chief Financial Officer, which was announced on August 4, 2015. AAU: 0.57 (+0.02), AAU.VN: 0.020 (+0.010)
Almaden Enters Into Mill Purchase Option Agreement; Significantly Reduces Capital Cost of Ixtaca "Ramp-Up" Scenario
Marketwired - Mon Oct 19, 3:00PM CDT
Almaden Minerals Ltd. ("Almaden" or the "Company"
(TSX: AMM)(NYSE MKT: AAU) is pleased to announce that it has entered into an option agreement entitling it to purchase assets (the "Assets" which, when taken together, constitute the Rock Creek mill. The Rock Creek mill is located just outside of Nome, Alaska. The mill was built to process 7,000 tonnes per day, and includes a three-stage crushing plant, gravity circuit, ball mill, flotation cells and leaching facilities. Also included in the Assets are conveyors, metallurgical and chemical fire assay laboratories, a water treatment plant, full electrical circuitry including generators, and a number of spare parts for the ball mill and crushers. The Rock Creek mill only operated for several months before the mining operation was curtailed in 2008 and has been kept in excellent condition during subsequent care and maintenance. AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Issues Inaugural CSR Report
Marketwired - Wed Sep 16, 3:00PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company"
; (TSX: AMM); (NYSE MKT: AAU) is pleased to announce that it has issued its inaugural report concerning its community-related activities at the Ixtaca project in Puebla State, Mexico. AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
AndeanGold Announces Up-Date on Audited Financial Statements and Default Status
ACCESSWIRE - Tue Sep 15, 2:20PM CDT
VANCOUVER, BC / ACCESSWIRE / September 15, 2015 / AndeanGold Ltd. (TSXV: AAU) (BVL: AAU) ("the Company" or "AndeanGold"
reports that, further to its news releases of August 4, 2015, August 13, 2015 and August 27, 2015 announcing the delay in the filing date of its audited financial statements and the subsequent granting of a Management Cease Trade Order by the British Columbia Securities Commission on July 30, 2015, the Company is continuing its search for a new Chief Financial Officer and is endeavoring to complete its audit as early as is practicable. AAU: 0.57 (+0.02), AAU.VN: 0.020 (+0.010)
Almaden Provides Ixtaca Metallurgical Program Update: Confirms High Limestone Gravity/Flotation/Leach Recoveries for Gold and Silver
Marketwired - Mon Sep 14, 3:07PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company"
(TSX: AMM) (NYSE MKT: AAU) is pleased to report on the Company's 100% owned Ixtaca gold-silver deposit located in Puebla State, Mexico and the progress of its on-going Pre-Feasibility ("PFS" level metallurgical test work program. The focus of the ongoing metallurgical test work program has been on the limestone material. Reported today are preliminary, non-optimised results from the leaching flotation concentrates. Key results of the test work reported today include the following: AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02)
Almaden Confirms Almadex Trading Date
Marketwired - Thu Aug 13, 3:35PM CDT
Almaden Minerals Ltd. ("Almaden" or the "Company"
(TSX: AMM) (NYSE MKT: AAU) is pleased to announce that the TSX Venture Exchange (the "TSXV" has issued a bulletin stating that the common shares (the "Almadex Shares" of Almadex Minerals Limited ("Almadex" will commence trading on the TSXV at the open of trading on Friday, August 14, 2015. The Almadex Shares will trade under the symbol "AMZ". AAU: 0.57 (+0.02), AMM.TO: 0.78 (+0.02), AMZ.VN: 0.150 (unch)
Anchor BanCorp Wisconsin Inc. Reports Third Quarter Earnings of $15.5 Million or $1.62 Per Diluted Share
GlobeNewswire - Thu Oct 29, 8:30AM CDT
Anchor BanCorp Wisconsin Inc. (the "Company"
(NASDAQ:ABCW), and its wholly-owned subsidiary, AnchorBank, fsb (the "Bank" , today announced financial results for the quarter ended September 30, 2015. The Company recorded a profitable quarter with net income of $15.5 million, or $1.62 per diluted common share. Pre-tax net income for the quarter ended September 30, 2015 of $25.9 million, or $2.71 per diluted share, included a negative provision for loan losses of $22.4 million, or $2.34 per diluted share, which was partially offset by $1.5 million in expense related to early lease termination expenses associated with several previously announced operational efficiency initiatives. Management anticipates these operational efficiency initiatives will result in annual net cost savings of approximately $5.4 million related to reduced compensation, occupancy and other operating costs. ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Reports Second Quarter Earnings of $107.5 Million or $11.37 Diluted Earnings Per Share Including a $103.0 Million Reversal of the Deferred Tax Asset Valuation Allowance
GlobeNewswire - Thu Jul 30, 4:30PM CDT
Anchor BanCorp Wisconsin Inc. (the "Company"
(NASDAQ:ABCW) and its wholly-owned subsidiary, AnchorBank, fsb (the "Bank" today announced its financial results for the quarter ended June 30, 2015. The Company recorded a strong and profitable quarter with net income of $107.5 million or $11.37 per diluted common share. Net income for the quarter ended June 30, 2015 includes a one-time income tax benefit, net of current quarter provision, of $103.0 million or $10.89 per diluted share primarily resulting from the reversal of substantially all of the Company's net deferred tax asset valuation allowance. Pre-tax income of $4.5 million or $0.48 per diluted share included the impact of one-time gains and costs associated with several previously announced operational efficiency initiatives during the quarter ended June 30, 2015. Management anticipates these initiatives will result in annual net cost savings of approximately $5.4 million related to reduced compensation, occupancy and other operating costs. ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Second Quarter 2015 Earnings Release Date and Conference Call
GlobeNewswire - Thu Jul 30, 3:30PM CDT
Second Quarter Financial Results Scheduled for Release
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Results of Operational Efficiency Measures
GlobeNewswire - Tue Jun 30, 4:45PM CDT
Anchor BanCorp Wisconsin Inc. (the "Company"
(NASDAQ:ABCW) today announced the anticipated financial results of the operational efficiency measures introduced previously. As the Company announced on April 9, 2015, AnchorBank, fsb ("AnchorBank" , a wholly owned subsidiary of the Company, has taken several actions to address and improve overall operational efficiency. Management anticipates that these actions will result in an annual net cost savings related to reduced compensation, occupancy and other operating costs of approximately $5.4 million. The actions will be completed by the third quarter of 2015. ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Finalizes Sale of Viroqua Branch to Royal Bank
GlobeNewswire - Mon May 18, 8:30AM CDT
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has finalized the sale of its Viroqua retail banking branch to Royal Bank of Elroy, Wisconsin as previously announced. The transaction closed today following receipt of the necessary regulatory approvals and satisfaction of customary closing conditions. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin reports Q1 results
Seeking Alpha - at Seeking Alpha - Thu Apr 30, 8:11AM CDT
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Reports First Quarter Earnings of $6.1 Million or $0.65 Earnings Per Share
GlobeNewswire - Thu Apr 30, 8:00AM CDT
Anchor BanCorp Wisconsin Inc. (the "Company"
(Nasdaq:ABCW) today announced its financial results for the quarter ended March 31, 2015. Anchor recorded a strong and profitable quarter with net income of $6.1 million or $0.65 per diluted common share. ABCW: 44.47 (-0.24)
AnchorBank Takes Actions to Improve Operational Efficiency
GlobeNewswire - Thu Apr 09, 8:05AM CDT
Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW) today announced several actions to address and improve the Company's overall operational efficiency, following a successful recapitalization in late 2013 and initial public offering in 2014.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin EPS of $0.55
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 5:27AM CST
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Fourth Quarter and Year End Results
GlobeNewswire - Fri Feb 06, 5:30PM CST
Anchor BanCorp Wisconsin Inc. (the "Company"
(Nasdaq:ABCW) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014. Anchor concluded a strong, profitable year with net income of $14.6 million or $1.60 per diluted common share. ABCW: 44.47 (-0.24)
Quarterly Report Card: Special Research on Ames National, Anchor Bancorp,Anchor BanCorp Wisconsin, Arrow, and ASB Bancorp
PR Newswire - Thu Feb 05, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ames National (NASDAQ: ATLO), Anchor Bancorp (NASDAQ: ANCB), Anchor BanCorp Wisconsin (NASDAQ: ABCW), Arrow (NASDAQ: AROW), and ASB Bancorp (NASDAQ: ASBB). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AROW: 28.13 (+0.04), ATLO: 24.29 (+0.06), ASBB: 25.75 (-0.24), ABCW: 44.47 (-0.24), ANCB: 25.23 (-0.30)
Anchor BanCorp Wisconsin Inc. Announces Definitive Agreement to Sell Viroqua Branch
GlobeNewswire - Tue Jan 27, 5:35PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Viroqua branch to Royal Bank of Elroy, Wisconsin. The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of May 2015. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Finalizes Sale of Richland Center Branch to The Peoples Community Bank
GlobeNewswire - Wed Dec 31, 3:56PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has finalized the sale of its Richland Center branch to The Peoples Community Bank (Peoples) as previously announced. The transaction closed today following receipt of the necessary regulatory approvals and satisfaction of customary closing conditions. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. to Join Multiple Russell Indexes
GlobeNewswire - Fri Dec 19, 3:30PM CST
Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW) today announced that it was included on the preliminary list of quarterly initial public offering additions to the broad-market Russell Global(R), Russell 3000(R), Russell 2000(R) and Russell Microcap(R) Indexes to be effective at the close of the U.S. market on Friday, December 19, 2014, according to a preliminary list of additions posted December 15, 2014 on www.russell.com/indexes.
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin reports Q3 profit
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:52PM CST
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin Inc. Announces Third Quarter Results
GlobeNewswire - Tue Nov 04, 4:07PM CST
Anchor BanCorp Wisconsin Inc. (the "Company"
(Nasdaq:ABCW), today announced its financial results for the quarter ended September 30, 2014. Net income was $5.0 million for the quarter compared to $2.6 million in the quarter ended June 30, 2014 and compared to net income of $113.3 million for the quarter ended September 30, 2013. Earnings per share were $0.55 for the quarter compared to $0.29 for the quarter ended June 30, 2014, and $5.47 per share for the quarter ended September 30, 2013. Income per share available to common equity was $10.24 for the quarter ended September 30, 2013. The prior year quarter income includes non-recurring extinguishment of debt income of $134.5 million which occurred as part of the recapitalization transaction we completed in September, 2013. ABCW: 44.47 (-0.24)
Anchor Bancorp Wisconsin Inc. Announces Definitive Agreement to Sell Richland Center Branch
GlobeNewswire - Thu Oct 30, 5:30PM CDT
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Richland Center retail banking branch to The Peoples Community Bank (Peoples). The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of December 2014. Financial terms of the transaction were not disclosed.
ABCW: 44.47 (-0.24)
U.S. IPO Weekly Recap: With Just 3 IPOs, More Companies Postpone Than Go Public
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 26, 12:22PM CDT
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those...
ABCW: 44.47 (-0.24), PRTO: 13.38 (-0.60)
Nice start for Anchor BanCorp after IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:52AM CDT
ABCW: 44.47 (-0.24)
Anchor BanCorp Wisconsin prices IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 6:52AM CDT
ABCW: 44.47 (-0.24)
BUYINS.NET: DANG, NEWS, ARII, ACOR, IVZ, EJ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 16, 6:27AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of E Commerce China Dangdang Inc (NYSE
ANG), Newstar Financial Inc (NASDAQ:NEWS), American Railcar Industries Inc (NASDAQ:ARII), Acorda Therapeutics Inc (NASDAQ:ACOR), Invesco Ltd (NYSE:IVZ), E-House (China) Holdings Ltd (NYSE:EJ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: NEWS: 8.35 (+0.30), ARII: 48.38 (-0.57), DANG: 7.19 (-0.01), IVZ: 31.60 (+0.26), ACOR: 39.30 (+0.83), EJ: 6.19 (+0.04)
Acorda Therapeutics Has Returned 19.4% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Mon Dec 14, 5:07PM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 19.41% as of today's recent price of $37.16.
ACOR: 39.30 (+0.83)
Acorda Presents Analyses on Use of Healthcare Services for Seizure Clusters at American Epilepsy Society Annual Meeting
Business Wire - Tue Dec 08, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced analyses from a study showing the effect of rescue medication for seizure clusters on both clinical outcomes and healthcare resource utilization. The study found there were more adverse outcomes and greater use of healthcare resources among those who did not always use a rescue medication to treat seizure clusters, compared to those who always used a rescue medication. Seizure clusters are defined as multiple, distinct seizures that occur over a 24-hour period. These analyses were presented at the 69th Annual Meeting of the American Epilepsy Society in Philadelphia, PA.
ACOR: 39.30 (+0.83)
Acorda Initiates Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines
Business Wire - Thu Dec 03, 6:01AM CST
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced initiation of enrollment in the first clinical study of CVT-427, an investigational agent under development for the acute treatment of migraines.
ACOR: 39.30 (+0.83)
BUYINS.NET: BFIN, SLW, CF, NEWS, ACOR, RZG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 02, 10:54PM CST
November 18, 2015
NEWS: 8.35 (+0.30), BFIN: 13.10 (+0.17), CF: 41.02 (+0.21), SLW: 12.56 (+0.01), ACOR: 39.30 (+0.83), RZG: 82.50 (+0.94)
NATIONAL DISABILITY INSTITUTE AND ACORDA THERAPEUTICS EXPAND FINANCIAL WELLNESS PROGRAM TO REACH MORE PEOPLE
GlobeNewswire - Wed Dec 02, 10:35AM CST
On December 9th, National Disability Institute (NDI) will launch the fifth annual Financial Wellness Program, designed to help people living with disabilities plan for their financial futures. Expert guests with backgrounds in law, finance and public benefits will share their insight on topics including taxes, employment, Social Security and credit. All resources and information presented will be specially tailored to address and remedy the unique financial challenges faced by individuals living with a range of disabilities. Last year, thousands of people registered for webinars, made available free of charge with support from Acorda Therapeutics.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Up 23.6% Since SmarTrend Uptrend Call (ACOR)
Comtex SmarTrend(R) - Mon Nov 30, 10:28AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 23.55% as of today's recent price of $38.45.
ACOR: 39.30 (+0.83)
Acorda Therapeutics to Present at the Oppenheimer Annual Healthcare Conference
Business Wire - Mon Nov 30, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Oppenheimer Healthcare Conference in New York on Tuesday, December 8 at 11:30 am.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Has Returned 20.6% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Mon Nov 23, 9:29AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 2 months, Acorda Therapeutics has returned 20.57% as of today's recent price of $37.52.
ACOR: 39.30 (+0.83)
Bristol-Myers' Opdivo Gets Priority Review from the FDA
Zacks Equity Research - Zacks Investment Research - Tue Nov 17, 12:50PM CST
Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.
GILD: 102.83 (+0.86), ABBV: 56.94 (+0.55), ACOR: 39.30 (+0.83), BMY: 69.74 (-0.48)
Shares of ACOR Up 19.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 16, 9:22AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 1 month, Acorda Therapeutics has returned 19.38% as of today's recent price of $37.15.
ACOR: 39.30 (+0.83)
Joel Marcus, CEO of Alexandria Real Estate Equities, Inc., Receives Lifetime Achievement Award from Biotech Executives
PR Newswire - Thu Nov 12, 7:54AM CST
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA urban innovation cluster locations, announced today that Joel S. Marcus, chairman, chief executive officer and founder, was honored with the NY/NJ CEO Lifetime Achievement Award in recognition of his leadership in the life science community. Mr. Marcus received the award on Wednesday, Nov. 11 during the NY/NJ CEO Conference, hosted by Boston Biotech Conferences, at the Apella(TM) event space at the Alexandria Center® for Life Science - New York City. The award was presented by esteemed past award honorees Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University; Ron Cohen, M.D., president and chief executive officer of Acorda Therapeutics, Inc. and George Yancopoulos, M.D., Ph.D., founding scientist, president and chief scientific officer of Regeneron Pharmaceuticals, Inc.
ARE: 90.03 (+0.38), ACOR: 39.30 (+0.83), REGN: 554.25 (-2.20)
Acorda Therapeutics to Present at Two Investor Conferences in November
Business Wire - Tue Nov 10, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during November.
ACOR: 39.30 (+0.83)
Acorda Therapeutics Shares Up 20.7% Since SmarTrend's Buy Recommendation (ACOR)
Comtex SmarTrend(R) - Fri Nov 06, 4:47PM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on October 5th, 2015 at $31.12. In approximately 1 month, Acorda Therapeutics has returned 20.66% as of today's recent price of $37.55.
ACOR: 39.30 (+0.83)
Why Acorda Therapeutics (ACOR) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 7:52AM CST
Acorda Therapeutics is a biotechnology company that is seeing solid activity on the earnings estimate revision front
ACOR: 39.30 (+0.83)
Looking for a Top Momentum Stock? 3 Reasons Why Acorda Therapeutics (ACOR) is a Great Choice
Zacks Equity Research - Zacks Investment Research - Mon Nov 02, 7:47AM CST
Acorda Therapeutics has a great combination of momentum score and favorable Zacks Rank, which makes it an impressive pick
ACOR: 39.30 (+0.83)
Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 8:40AM CDT
Vertex's (VRTX) third quarter results were strong with the company posting a narrower-than-expected loss and revenues coming in well above expectations.
VRTX: 116.89 (-0.39), AMAG: 27.33 (+0.47), ACOR: 39.30 (+0.83)
Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents" . ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
BUYINS.NET: ACST SqueezeTrigger Price is $1.09. There is $12,810 That Short Sellers Still Need To Cover.
M2 - Thu Oct 15, 11:43AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ACCESS TRADEONE.COM (NASDAQ:ACST) in real time and just received an alert that ACST is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 4200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.09. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ACST: 2.37 (+0.76)
TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 2.37 (+0.76)
Acasti reports 2Q loss
Automated Insights - Wed Oct 14, 4:45PM CDT
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Wednesday reported a loss of $972,000 in its fiscal second quarter.
ACST: 2.37 (+0.76)
Acasti Announces Second Quarter Results
GlobeNewswire - Wed Oct 14, 4:10PM CDT
-- Important progress made in FDA discussions on development pathway for CaPre(R)
ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti approves one for ten reverse stock split
M2 - Wed Sep 30, 5:23AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) declared on Tuesday that it will consolidate its issued and outstanding Class A common shares on the ratio of one post-consolidation common share for every ten pre-consolidation common shares provided each fractional common share shall be rounded up.
ACST: 2.37 (+0.76)
Acasti Announces 1-for-10 Reverse Stock Split
GlobeNewswire - Tue Sep 29, 6:00AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that in order to regain compliance with NASDAQ Minimum Bid Price Rules, it will consolidate the issued and outstanding Class A common shares ("Common Shares" of the Corporation (the "Consolidation" on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares (the "Consolidation Ratio" , provided that each fractional Common Share that results from the Consolidation shall be rounded up. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 305.98 (+1.32), ACST: 2.37 (+0.76), ISIS: 58.89 (+2.47), AZN: 33.49 (+0.23), TKMR: 10.83 (+0.58), CBAY: 1.44 (+0.04), NVS: 85.86 (+0.58)
Acasti announces award of incentive stock options to its board
M2 - Thu Aug 20, 3:10AM CDT
Acasti Pharma (Nasdaq CM:ACST) (TSX:APO.V) Wednesday awarded an aggregate of 500,000 incentive stock options.
ACST: 2.37 (+0.76)
Acasti Announces Grant of Stock Options
GlobeNewswire - Wed Aug 19, 4:05PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the grant of an aggregate of 500,000 incentive stock options under the Corporation's Stock Option Plan for its Board of Directors. The options will vest annually over a period of three years and will entitle its holder to purchase one common share of Acasti at a price of CDN $0.48 until August 19, 2022. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Mario Paradis Appointed CFO of Neptune and Acasti
GlobeNewswire - Wed Aug 05, 4:30PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(NASDAQ:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (NASDAQ:ACST) (TSX-V:APO), a Neptune subsidiary, announce the appointment of Mario Paradis as Chief Financial Officer (CFO), starting August 24, 2015. ACST: 2.37 (+0.76), NTB.TO: 1.41 (+0.06), NEPT: 1.05 (+0.06), APO.VN: 3.320 (+1.100)
Acasti falls to Q1 net loss of USD966,000
M2 - Tue Jul 14, 4:39AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Monday its net loss of USD966,000 for the first quarter ended 31 May 2015.
ACST: 2.37 (+0.76)
Acasti Announces First Quarter Results
GlobeNewswire - Mon Jul 13, 4:05PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the first quarter ended May 31, 2015. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Pharma net loss improves in FQ4 and FY15
Seeking Alpha - at Seeking Alpha - Thu May 28, 7:23AM CDT
ACST: 2.37 (+0.76)
Acasti Pharma reports FQ4 results
Seeking Alpha - at Seeking Alpha - Wed May 27, 4:50PM CDT
ACST: 2.37 (+0.76)
Acasti Announces Fourth Quarter and Fiscal Year Results
GlobeNewswire - Wed May 27, 4:37PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its operating and financial results for the fourth quarter and fiscal year ended February 28, 2015. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of Shareholders
GlobeNewswire - Wed May 27, 4:35PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, today announced its slate of director nominees for election at its next Annual and Special Meeting ("ASM" of shareholders to be held on July 14, 2015. The slate is comprised of four current directors, and two new director nominees. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule
GlobeNewswire - Mon May 11, 9:48AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ" that it is eligible for an additional 180 calendar days, until November 2, 2015, to regain compliance with the minimum $1.00 per share requirement for continued listing. ACST: 2.37 (+0.76), APO.VN: 3.320 (+1.100)
Zacks Investment Ideas feature highlights: Netgear, Activision Blizzard, AeroCentury, Biotelemetry and A-Mark Precious
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:30AM CST
Zacks Investment Ideas feature highlights: Netgear, Activision Blizzard, AeroCentury, Biotelemetry and A-Mark Precious
ATVI: 38.84 (+0.13), BEAT: 12.08 (+0.16), ACY: 12.25 (-0.70), NTGR: 43.99 (+0.50), AMRK: 17.26 (+0.63)
5 Strong Stocks in Stronger Industries
David Bartosiak - Zacks Investment Research - Thu Dec 03, 11:48AM CST
5 Strong Stocks in Stronger Industries
ATVI: 38.84 (+0.13), ACY: 12.25 (-0.70), BEAT: 12.08 (+0.16), NTGR: 43.99 (+0.50), AMRK: 17.26 (+0.63)
3 Reasons Value Stock Investors Will Love AeroCentury (ACY)
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 7:48AM CST
There are numerous reasons that make AeroCentury a great choice for value investors
ACY: 12.25 (-0.70)
Shares of ACY Down 14.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 17, 9:26AM CST
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 2 months, AeroCentury has returned 14.02% as of today's recent price of $8.65.
ACY: 12.25 (-0.70)
AeroCentury Corp. Earns $1.3 Million, or $0.81 per Share, in 3Q15; Portfolio Utilization Improves to 94%
PR Newswire - Mon Nov 09, 4:00PM CST
AeroCentury Corp. (NYSE MKT: ACY), an independent aircraft leasing company, today reported earnings totaling $1.3 million, or $0.81 per diluted share, in the third quarter of 2015, compared to $1.4 million, or $0.87 per diluted share, in the second quarter of 2015. Third quarter profits reflect an improvement in utilization as the Company continues to adjust the composition of its portfolio of regional aircraft and engines. Following the $11.7 million non-cash, pre-tax write-down of certain older aircraft, the net loss in the third quarter of 2014 was $8.2 million, or ($5.34) per diluted share.
ACY: 12.25 (-0.70)
AeroCentury Shares Down 12.1% Since SmarTrend's Sell Call (ACY)
Comtex SmarTrend(R) - Wed Nov 04, 12:19PM CST
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 12.09% as of today's recent price of $8.84.
ACY: 12.25 (-0.70)
8.7% Return Seen to Date on SmarTrend AeroCentury Call (ACY)
Comtex SmarTrend(R) - Wed Oct 28, 10:47AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 8.75% as of today's recent price of $9.18.
ACY: 12.25 (-0.70)
Why Rent-A-Center Stock Plunged after Q3 Earnings Results
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 9:50AM CDT
Although Rent-A-Center (RCII) continued with its positive earnings surprise streak for the third successive quarter, it missed on revenues and lowered its earnings forecast which took a toll on the stock.
RCII: 15.67 (+0.08), MGRC: 26.09 (+0.27), ACY: 12.25 (-0.70), AAN: 22.74 (+0.29)
AeroCentury Shares Down 9.5% Since SmarTrend's Sell Call (ACY)
Comtex SmarTrend(R) - Wed Oct 21, 9:37AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 1 month, AeroCentury has returned 9.54% as of today's recent price of $9.10.
ACY: 12.25 (-0.70)
AeroCentury Has Returned 13.1% Since SmarTrend Recommendation (ACY)
Comtex SmarTrend(R) - Tue Oct 13, 9:55AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 3 weeks, AeroCentury has returned 13.11% as of today's recent price of $8.74.
ACY: 12.25 (-0.70)
CBOE Holdings Well Poised on Business Model, Cost Control
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 2:55PM CDT
On Oct 6, 2015, we issued an updated research report on CBOE Holdings, Inc. (CBOE).
AER: 40.36 (+0.19), ACAS: 13.95 (-0.03), CBOE: 65.89 (-1.50), ACY: 12.25 (-0.70)
Downtrend Call Working As AeroCentury Stock Falls 13.5% (ACY)
Comtex SmarTrend(R) - Tue Oct 06, 9:42AM CDT
SmarTrend identified a Downtrend for AeroCentury (AMEX:ACY) on September 21st, 2015 at $10.06. In approximately 2 weeks, AeroCentury has returned 13.52% as of today's recent price of $8.70.
ACY: 12.25 (-0.70)
Shares of ACY Up 21.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 15, 10:12AM CDT
SmarTrend identified an Uptrend for AeroCentury (AMEX:ACY) on August 24th, 2015 at $9.68. In approximately 3 weeks, AeroCentury has returned 21.38% as of today's recent price of $11.75.
ACY: 12.25 (-0.70)
CBOE Holdings to Launch AFX with Environmental Financial
Zacks Equity Research - Zacks Investment Research - Fri Sep 11, 9:20AM CDT
CBOE Holdings, Inc. (CBOE) recently entered into an agreement with Environmental Financial Products, LLC ("EFP"
to form and launch American Financial Exchange ("AFX" . CME: 95.00 (-0.15), ACAS: 13.95 (-0.03), CBOE: 65.89 (-1.50), ACY: 12.25 (-0.70)
AeroCentury Up 26.0% Since SmarTrend Uptrend Call (ACY)
Comtex SmarTrend(R) - Tue Sep 08, 9:47AM CDT
SmarTrend identified an Uptrend for AeroCentury (AMEX:ACY) on August 24th, 2015 at $9.68. In approximately 2 weeks, AeroCentury has returned 26.03% as of today's recent price of $12.20.
ACY: 12.25 (-0.70)
The Zacks Analyst Blog Highlights: AeroCentury, Central Garden & Pet, LGI Homes, NCI and U.S. Concrete
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: AeroCentury, Central Garden & Pet, LGI Homes, NCI and U.S. Concrete
LGIH: 25.87 (+1.02), CENT: 14.31 (-0.16), ACY: 12.25 (-0.70), NCIT: 14.60 (-0.37), USCR: 53.99 (+0.57)
5 Best Performing Stocks in August
Swarup Gupta - Zacks Investment Research - Tue Sep 01, 10:26AM CDT
Markets experienced a dismal month, weighed down by concerns about China and uncertainty over the timing of a rate hike.
LGIH: 25.87 (+1.02), CENT: 14.31 (-0.16), ACY: 12.25 (-0.70), DIS: 113.15 (+0.99), WMT: 60.16 (+0.52), NCIT: 14.60 (-0.37), VIAB: 41.14 (+0.16), USCR: 53.99 (+0.57)
New Strong Buy Stocks for August 21st
Zacks Equity Research - Zacks Investment Research - Fri Aug 21, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
PRSS: 3.74 (unch), FTD: 27.63 (+0.56), ACY: 12.25 (-0.70), EIG: 27.48 (-0.07), ANCB: 25.23 (-0.30)
Aduro's CRS-207/GVAX Pancreas Gets Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 3:20PM CST
Aduro's (ADRO) CRS-207/GVAX Pancreas combination gets Orphan drug designation in the EU.
ADRO: 33.08 (+1.94), ACHN: 9.82 (+0.11), ANIK: 38.17 (+0.67), CORT: 4.70 (+0.19)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 33.08 (+1.94), PFE: 32.26 (unch), ARQL: 2.16 (unch), BMY: 69.71 (-0.51), GSK: 39.85 (+0.51), VSTM: 1.82 (+0.08), SNTA: 0.32 (unch), MRK: 53.51 (+0.61), JUNO: 45.99 (-0.76), NVS: 85.83 (+0.55), CXRX: 38.15 (+0.54), FPRX: 42.31 (+2.07)
The Only Bit of "Good News" From 2015
ACCESSWIRE - Mon Dec 14, 10:08AM CST
WINDSOR, ON / ACCESSWIRE / December 14, 2015 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to mention a few highlights from 2014/ 2015 in the crazy world of biotech investing. IMMU: 3.04 (+0.12), ADRO: 33.08 (+1.94), MRK: 53.51 (+0.61), AMGN: 163.32 (+0.70), LLY: 85.00 (-0.52), THLD: 0.50 (+0.02), BMY: 69.71 (-0.51)
Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 and GVAX Pancreas for the Treatment of Pancreatic Cancer
GlobeNewswire - Mon Dec 14, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 and GVAX for the treatment of pancreatic cancer.
ADRO: 33.08 (+1.94)
Aduro Biotech doses first lung cancer patient under Phase 1 Study of ADU-214
M2 - Fri Dec 11, 3:44AM CST
Oncology company Aduro Biotech (NasdaqGS:ADRO) reported on Thursday that it has commenced treatment of the first patient in the Phase 1 study of ADU-214 for lung cancer.
ADRO: 33.08 (+1.94)
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer
GlobeNewswire - Thu Dec 10, 3:15PM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the start of the Phase 1 study of ADU-214 (also known as JNJ-64041757), a LADD immuno-oncology therapy for the treatment of lung cancer, with the dosing of the first patient in the trial. Janssen Biotech, Inc., Aduro's license partner for ADU-214, is conducting the multi-center study.
ADRO: 33.08 (+1.94)
Aduro Biotech to Present at Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 02, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer's 26 Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
ADRO: 33.08 (+1.94)
Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 28, 6:21AM CST
Source: Bristol-Myers Squibb. One of the most important new drugs to win regulatory approval this year is Opdivo, a novel medicine developed by Bristol-Myers Squibb that keeps cancer from evading detection by a patient's immune system. Opdivo...
ADRO: 33.08 (+1.94), BMY: 69.71 (-0.51), CELG: 113.93 (+0.79)
Aduro Biotech to Present at NASDAQ Investor Conference
GlobeNewswire - Fri Nov 27, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 33 NASDAQ Investor Conference in London, UK on Tuesday, December 1, 2015, at 8:00 am Greenwich Mean Time.
ADRO: 33.08 (+1.94)
Aduro Biotech Confirms All Clinical Trials Continue Unaltered and as Planned
GlobeNewswire - Tue Nov 24, 4:09PM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it will hold a conference call tomorrow November 25, 2015 at 5:00 am Pacific Standard Time. To participate in the conference call, please dial (855) 283-3941 (domestic) or (330) 863-3274 (international) and refer to conference ID 90656408. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the general public under the Investors section of the company's website at www.aduro.com.
ADRO: 33.08 (+1.94)
Why Aduro Biotech Is Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 24, 2:03PM CST
Source: Aduro BioTech W hat: After reporting that a patient developed a serious infection while receiving its promising immunotherapy for the treatment of pancreatic cancer, shares in Aduro BioTech fell by 15% earlier today. So...
ADRO: 33.08 (+1.94), BMY: 69.71 (-0.51)
Aduro Biotech tops Street 3Q forecasts
Automated Insights - Mon Nov 23, 7:09AM CST
BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Monday reported third-quarter profit of $567,000.
ADRO: 33.08 (+1.94)
Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma
GlobeNewswire - Mon Nov 23, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 for the treatment of malignant pleural mesothelioma (MPM).
ADRO: 33.08 (+1.94)
Aduro Biotech Announces Third Quarter 2015 Financial Results
GlobeNewswire - Mon Nov 23, 7:00AM CST
Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter and nine months ended September 30, 2015. Net income was $0.6 million for the third quarter of 2015, or $0.01 per share, and net loss was $42.3 million, or $1.09 per share, for the nine months ended September 30, 2015. This compares to a net loss of $4.7 million, or $14.24 per share, and $16.1 million, or $52.47 per share respectively, for the same periods in 2014.
ADRO: 33.08 (+1.94)
Aduro (ADRO) Creates Subsidiary, Aduro Biotech Europe
Zacks Equity Research - Zacks Investment Research - Fri Nov 20, 1:50PM CST
Aduro (ADRO) has established a subsidiary in the EU, which will operate as Aduro Biotech Europe.
ADRO: 33.08 (+1.94), ACHN: 9.82 (+0.11), ANIK: 38.17 (+0.67), CORT: 4.70 (+0.19)
Aduro Biotech Europe's Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured as Keynote Speaker on Immunomodulatory Antibodies at ESMO Symposium on Immuno-Oncology 2015
Thomson Reuters ONE - Fri Nov 20, 7:00AM CST
BERKELEY, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a clinical-stage immunotherapy company, today announced the presentation of an overview of novel antibody and combination strategies designed to stimulate durable anti-tumor response at the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology 2015, taking place November 20-21, 2015, in Lausanne, Switzerland. The presentation was featured in a keynote lecture delivered at the ESMO symposium by Andrea van Elsas, Ph.D., chief scientific officer of Aduro Biotech Europe, titled, "Immunomodulatory Antibodies Beyond PD-1."
ADRO: 33.08 (+1.94)
Aduro Biotech Establishes European Subsidiary
GlobeNewswire - Thu Nov 19, 3:05PM CST
-Recently Acquired BioNovion Site to Become Aduro Biotech Europe-
ADRO: 33.08 (+1.94)
Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-741 in Prostate Cancer
GlobeNewswire - Wed Nov 18, 7:00AM CST
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it has received a milestone payment from Janssen Biotech, Inc. for Aduro's submission of an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer (mCRPC).
ADRO: 33.08 (+1.94)
Aduro Biotech Announces Five Poster Presentations at the Society of Immunotherapy of Cancer Annual Meeting
GlobeNewswire - Mon Nov 09, 7:00AM CST
Posters highlight:
ADRO: 33.08 (+1.94)
(0)
(0)Chinook Therapeutics, Inc. (KDNY) Stock Research Links
Scroll down for more posts ▼